title: Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator.
abstract: Drug resistance has emerged as a major impediment in the treatment of leishmaniasis. Alkyl-lysophospholipids (ALP), originally developed as anticancer drugs, are considered to be the most promising antileishmanial agents. In order to anticipate probable clinical failure in the near future, we have investigated possible mechanisms of resistance to these drugs in Leishmania spp. The results presented here support the involvement of a member of the ATP-binding cassette (ABC) superfamily, the Leishmania P-glycoprotein-like transporter, in the resistance to ALP. (i) First, a multidrug resistance (MDR) Leishmania tropica line overexpressing a P-glycoprotein-like transporter displays significant cross-resistance to the ALP miltefosine and edelfosine, with resistant indices of 9.2- and 7.1-fold, respectively. (ii) Reduced expression of P-glycoprotein in the MDR line correlates with a significant decrease in ALP resistance. (iii) The ALP were able to modulate the P-glycoprotein-mediated resistance to daunomycin in the MDR line. (iv) We have found a new inhibitor of this transporter, the sesquiterpene C-3, that completely sensitizes MDR parasites to ALP. (v) Finally, the MDR line exhibits a lower accumulation than the wild-type line of bodipy-C(5)-PC, a fluorescent analogue of phosphatidylcholine that has a structure resembling that of edelfosine. Also, C-3 significantly increases the accumulation of the fluorescent analogue to levels similar to those of wild-type parasites. The involvement of the Leishmania P-glycoprotein-like transporter in resistance to drugs used in the treatment of leishmaniasis also supports the importance of developing new specific inhibitors of this ABC transporter.
authors.affiliation: Instituto de Parasitología y Biomedicina "López-Neyra," Consejo Superior de Investigaciones Científicas, Granada, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Pérez-Victoria
authors.forename: F J
authors.initials: FJ
authors.lastname: Pérez-Victoria
authors.forename: A
authors.initials: A
authors.lastname: Parodi-Talice
authors.forename: I A
authors.initials: IA
authors.lastname: Jiménez
authors.forename: A G
authors.initials: AG
authors.lastname: Ravelo
authors.forename: S
authors.initials: S
authors.lastname: Castanys
authors.forename: F
authors.initials: F
authors.lastname: Gamarro
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000502:physiology*; D005453:Fluorescence; D006801:Humans; D007895:Leishmania tropica / Q000187:drug effects / Q000378:metabolism*; D021261:Parasitic Sensitivity Tests; D010742:Phospholipid Ethers / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C107991:ABCB6 protein, human; D018528:ATP-Binding Cassette Transporters; D000903:Antibiotics, Antineoplastic; D000981:Antiprotozoal Agents; D010742:Phospholipid Ethers; D010767:Phosphorylcholine; C026659:edelfosine; C039128:miltefosine; D003630:Daunorubicin